切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2017, Vol. 11 ›› Issue (02) : 74 -77. doi: 10.3877/cma.j.issn.1674-0807.2017.02.003

论著

促性腺激素释放激素受体在乳腺癌组织中的表达及其临床意义
陈玲1, 何菁1, 孟东1, 孙春雷1, 时伟锋1, 齐晓薇2, 金琳芳2, 徐闻欢3, 周士福1,†()   
  1. 1.214062 江苏无锡,江南大学附属医院普外科
    2.214062 江苏无锡,江南大学附属医院病理科
    3.214062 江苏无锡,江南大学附属医院肿瘤内科
  • 收稿日期:2016-08-08 出版日期:2017-04-01
  • 通信作者: 周士福
  • 基金资助:
    国家自然科学基金青年科学基金资助项目(81402487)江苏省自然科学基金青年基金资助项目(BK20140170)

Expression of gonadotropin releasing hormone receptor in breast cancer tissue and its clinical significance

Ling Chen1, Jing He1, Dong Meng1, Chunlei Sun1, Weifeng Shi1, Xiaowei Qi2, Linfang Jin2, Wenhuan Xu3, Shifu Zhou1,†()   

  1. 1.Department of General Surgery
    2.Department of Pathology
    3.Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214062, China
  • Received:2016-08-08 Published:2017-04-01
  • Corresponding author: Shifu Zhou
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈玲, 何菁, 孟东, 孙春雷, 时伟锋, 齐晓薇, 金琳芳, 徐闻欢, 周士福. 促性腺激素释放激素受体在乳腺癌组织中的表达及其临床意义[J/OL]. 中华乳腺病杂志(电子版), 2017, 11(02): 74-77.

Ling Chen, Jing He, Dong Meng, Chunlei Sun, Weifeng Shi, Xiaowei Qi, Linfang Jin, Wenhuan Xu, Shifu Zhou. Expression of gonadotropin releasing hormone receptor in breast cancer tissue and its clinical significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(02): 74-77.

目的

探讨促性腺激素释放激素受体(GnRH-R)在乳腺癌组织中的表达及其与患者临床病理特征的相关性。

方法

收集了2008年1 月至2010年12 月江南大学附属医院保存的104 例浸润性乳腺导管癌患者的手术切除标本进行回顾性分析。 应用免疫组织化学SP 法观察乳腺癌组织中GnRH-R的表达,研究GnRH-R 与乳腺癌患者临床病理特征之间的关系,并采用χ2 检验进行统计分析。

结果

乳腺癌组织中GnRH-R 的阳性表达率为66.3%(69/104)。 GnRH-R 的阳性表达率在luminal A 型、luminal B 型、HER-2 过表达型、三阴性乳腺癌患者中分别为5/11、61.4%(27/44)、8/16、87.9%(29/33),差异有统计学意义(χ2=11.407,P＜0.050)。 两两比较显示,GnRH-R 在三阴性乳腺癌的阳性表达率高于luminal A 型(χ2=8.455,P＜0.008)和HER-2 过表达型(χ2=8.361,P＜0.008)。 乳腺癌组织中GnRH-R的阳性表达率在不同年龄、组织学分级、淋巴结转移状态及临床分期的患者中,差异没有统计学意义(χ2=0.506,P=0.477; χ2 =0.007,P=0.936; χ2 =2.158,P=0.340; χ2 =0.007,P=0.936)。

结论

GnRH-R 在三阴性乳腺癌组织中呈高表达,可能为三阴性乳腺癌患者的治疗提供参考。

关键词: 乳腺肿瘤, 分子分型, 受体, GnRH

Objective

To investigate the expression of gonadotropin releasing hormone receptor(GnRH-R) in breast cancer tissue and its correlation with patients' clinicopathological characteristics.

Methods

We collected surgically resected specimens from 104 cases of invasive ductal breast cancer in the Affiliated Hospital of Jiangnan University from December 2010 to January 2008 for a retrospective study. The expression of GnRH-R in breast cancer tissue was detected by immunohistochemical SP method. The correlation between GnRH-R expression and patients' clinicopathological characteristics was analyzed using χ2 test.

Results

The positive rate of GnRH-R in invasive breast cancer tissue was 66.3% (69/104). With regards to different molecular subgroups, the positive rate of GnRH-R was 5/11 in luminal A subtype,61.4%(27/44)in luminal B subtype, 8/16 in HER-2 overexpression subtype and 87.9%(29/33)in triple negative subtype,indicating a significant difference(χ2=11.407,P＜0.050). The pairwise comparison showed that the positive expression rate of GnRH-R in triple negative subtype was significantly higher than that in luminal A subtype(χ2= 8.455,P＜0.008) or HER-2 overexpression subtype(χ2= 8.361,P＜0.008) respectively. The positive rates of GnRH-R in breast cancer tissues presented no significant difference in patients with different ages,histological grade, lymph node metastasis and clinical stages (χ2=0.506,P=0.477; χ2=0.007,P=0.936;χ2=2.158,P=0.340; χ2 =0.007,P=0.936).

Conclusion

GnRH-R is highly expressed in triple negative breast cancer tissue, which may provide references for the treatment of triple negative breast cancer.

Key words: Breast neoplasms, Molecular typing, Receptors, GnRH
图1 GnRH-R 在浸润性乳腺导管癌中的表达(SP ×40) 注:a 图为GnRH-R(-),b 图为GnRH-R(+),c 图为GnRH-R(+++),GnRH-R 为促性腺激素释放激素受体
表1 104 例浸润性乳腺癌组织中GnRH-R 表达与临床病理特征之间的关系
临床病理特征 例数 GnRH-R表达(例) χ2值 P值
阳性 阴性
年龄(岁)
≤45 31 19 12 0.506 0.477
＞45 73 50 23
组织学分级
1、2级 44 29 15 0.007 0.936
3级 60 40 20
淋巴结转移
0枚 62 38 24 2.158 0.340
1~3枚 27 19 8
≥4枚 15 12 3
分子分型
luminal A 11 5 6 11.407 0.010
luminal B 44 27 17
HER-2过表达 16 8 8
三阴性 33 29a,b 4
临床分期
Ⅰ、Ⅱ 86 54 32 2.813 0.093
Ⅲ、Ⅳ 18 15 3
[1]
Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues [J]. FEBS J, 2008, 275(22):5479-5495.
[2]
Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (review) [J]. Oncol Rep,2009,22(5):981-990.
[3]
Limonta P, Montagnani Marelli M, Mai S, et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies[J].Endocr Rev,2012,33(5):784-811.
[4]
李敏,吴小华,徐翠清,等. GnRHⅠ,GnRHⅡ及其受体在人卵巢恶性上皮性肿瘤细胞中的表达及意义[J]. 第四军医大学学报,2008,29(24):2281-2283.
[5]
Goldhirsch A,Winer EP,Coates AS,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol,2013,24(9):2206-2223.
[6]
DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women[J]. CA Cancer J Clin,2016,66(1):31-42.
[7]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[8]
Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs[J]. Annu Rev Med,1994,45:391-405.
[9]
Schubert A, Hawighorst T, Emons G, et al. Agonists and antagonists of GnRH-Ⅰand -Ⅱreduce metastasis formation by triple-negative human breast cancer cells in vivo[J]. Breast Cancer Res Treat,2011,130(3):783-790.
[10]
Buchholz S, Seitz S, Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH)and respond to LHRH antagonist cetrorelix with growth inhibition[J].Int J Oncol,2009,35(4):789-796.
[11]
Grundker C, Fost C, Fister S, et al. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDAMB-231 human breast cancer cells in vitro and in vivo[J]. Breast Cancer Res,2010,12(4): R49.
[12]
Emons G, Muller V, Ortmann O, et al. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells[J]. J Steroid Biochem Mol Biol,1998,65(1-6):199-206.
[13]
Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med,2015,372(10):923-932.
[14]
Schally AV,Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors [J]. Trends Endocrinol Metab, 2004, 15(7):300-310.
[15]
Harrison GS, Wierman ME, Nett TM, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells[J]. Endocr Relat Cancer,2004,11(4):725-748.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 笪东祝, 林凯, 王小蕊, 王开银, 王敏, 王玮, 李瑾, 刘俊. 低促甲状腺激素水平结节性甲状腺肿的发生发展与促甲状腺激素受体基因D727E 多态性的相关性研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 443-446.
[10] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号